Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

AI4HF Trustworthy Artificial Intelligence for Personalised Risk Assessment in Chronic Heart Failure

Coordinator
Stichting Netherlands Heart Institute, Netherlands
Runs
1 June 2023 to 31 May 2027
Status
Running
EU funding
€5.9m
Total cost
€5.9m
Partners
16 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101080430

What the project is doing

In the project's own words, from its summary on CORDIS.

Cardiovascular diseases remain the main cause of mortality worldwide; in particular, heart failure (HF) poses complex challenges in clinical practice, as it is associated with a significant variability in aetiologies, manifestations and risks, as well as in its progression and trajectories over time. Clinical risks of HF can vary from reduced cardiac function and regular hospitalisations, all the way to cardiac events and mortality.

There is a need for a personalised medicine approach to tailor the care models (i.e. lifestyle changes, medications, interventions) to each HF patient’s risk profile and hence optimise the clinical outcomes. Artificial intelligence (AI) solutions trained from multi-source cardiovascular data have the potential to dissect the precise characteristics of each patient and predict their likely trajectories at an early stage.

However, existing AI methods remain a far distance from clinical transfer and adoption due to a common and key limitation: their trustworthiness and acceptance by cardiologists and patients alike have not been achieved. AI4HF will develop the first trustworthy AI solutions for personalised risk assessment and management of HF patients. The project will build on a unique set of big data repositories, trustworthy AI methods, computational tools and clinical results from major EU-funded projects in cardiology.

To test robustness, fairness, transparency, usability and transferability, the validation with take place in eight clinical centres in both high- and low-to-middle-income countries in the EU and internationally. AI4HF will develop a comprehensive and standardised methodological framework for trustworthy and ethical AI development and evaluation based on the FUTURE-AI guidelines developed by the consortium members. AI4HF will be implemented through continuous multi-stakeholder engagement, taking into account clinical needs and patient preferences, as well as socio-ethical and regulatory perspectives.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Netherlands Heart InstituteUtrechtNetherlandsCoordinator
European Heart Network AisblBruxelles / BrusselBelgiumParticipant
Fakultni Nemocnice U Sv Anny V BrneBrnoCzechiaParticipant
Regenold GmbHBadenweilerGermanyParticipant
Ethniko Kentro Erevnas Kai Technologikis AnaptyxisThermi ThessalonikiGreeceParticipant
Barcelona Supercomputing Center Centro Nacional De SupercomputacionBarcelonaSpainParticipant
Fundacio Hospital Universitari Vall D'hebron - Institut De RecercaBarcelonaSpainParticipant
Universitat De BarcelonaBarcelonaSpainParticipant
Societe Europeenne De CardiologieBiotFranceParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Centro De Investigaciones Tecnologicas, Biomedicas Y MedioambientalesCallaoPEParticipant
Shine 2europe LdaCoimbraPortugalParticipant
Srdc Yazilim Arastirma Ve Gelistirme Ve Danismanlik Ticaret Anonim SirketiAnkaraTürkiyeParticipant
Muhimbili University of Health and Allied SciencesDar Es SalaamTZParticipant
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI